BioAlliance Pharma SA is looking ahead to three possibly transforming events in the second quarter of 2010 that could secure its standing as a recognised specialty pharmaceutical company in Europe.
An investigational drug for patients with Alzheimer’s disease, Dimebon (latrepirdine), has failed in a Phase 3 trial because it could not show statistically significant improvements in patients compared with placebo for cognition and global function.
Intercell AG expects to report data in 2010 on two late-stage vaccine candidates against hospital-acquired infections, conditions that have become serious in recent years because of bacterial resistance to marketed antibiotics.
UCB expects that three recently launched drugs will drive the company’s growth for the next decade following a period of extensive restructuring.
Merck KGaA of Germany has made an agreed bid for the US service provider, Millipore Corp, in a transaction valued at $7.2 billion, including net debt. The merged company is expected to have critical mass in bioresearch and bioprocessing.
The European Medicines Agency (EMA) is looking at ways it can work more closely with government bodies in Europe whose responsibility it is to decide whether or not to subsidize a new medicine based on its relative effectiveness.
The US Food and Drug Administration has approved Shire Plc’s treatment for Gaucher disease, Vpriv (velaglucerase alfa), under a special procedure where the review was completed in six months rather than the usual 10.
Ablynx NV expects that its heavy-chain-only antibody technology will show clinical progress in 2010 from its own and partnered programmes. It also expects to report progress on new delivery technologies.
The clot-dissolving investigational drug, desmoteplase, still has potential for treating patients with acute ischaemic stroke up to nine hours after the onset of symptoms, the drug’s developer, H. Lundbeck A/S, told an international conference.
After reviewing 50 possible acquisitions, and carrying out detailed negotiations with three, MorphoSys AG has concluded that there are no takeover opportunities that would significantly enhance its own antibody portfolio.